Human Metabolome Technologies Inc
TSE:6090
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
JP |
Human Metabolome Technologies Inc
TSE:6090
|
3.9B JPY | 13.6 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.7B USD | 34.8 | ||
US |
Danaher Corp
NYSE:DHR
|
195.1B USD | 21.6 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 35 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.4B USD | 26.2 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.3B CHF | 29.5 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 49.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 31.5 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.6B USD | 26.9 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.6B USD | 38 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR | 54.7 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.